health_text_en

Kexing Biopharm Introduces Eribulin Mesylate Injection, Expanding Its Overseas Product Portfolio

On the morning of January 3, Kexing Biopharm signed an international commercialization cooperation agreement on Eribulin Mesylate Injection, securing exclusive commercialization licensing and supply of the product from Xiling Lab Co., Ltd. in 36 countries. This is the fifth major breast cancer medication introduced by Kexing Biopharm, which further enriches its product portfolio for breast cancer treatment. […]

thaipr.net

8 ม.ค. 67

Menarini Group and Insilico Medicine Enter Global Exclusive License Agreement for Novel KAT6 Inhibitor for Potential Breast Cancer Treatment and Other Oncology Indications

The Menarini Group (“Menarini”), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. (“Stemline”), a wholly-owned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients, along with clinical stage generative artificial intelligence (AI)-driven biotechnology company Insilico Medicine (“Insilico”), today announced…

thaipr.net

5 ม.ค. 67

Therabody, the Global Leader In Wellness Technology, Defends Against Recent Patent Infringement Lawsuit Filed by Hyperice

As the leading percussive patent owner and the driving force behind many of today’s wellness innovations, Therabody will vigorously defend itself against the recent patent infringement lawsuit filed by Hyperice. Therabody, the leader in tech wellness and percussive massage therapy, announced today that it will be vigorously defending itself in the recent patent infringement lawsuit […]

thaipr.net

5 ม.ค. 67

JW Therapeutics Announces NMPA Acceptance of the Supplemental Biological License Application for Carteyva® in Patients with Relapsed or Refractory Mantle Cell Lymphoma

JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced that the National Medical Products Administration (NMPA) of China accepted the supplemental Biological License Application (sBLA) for its anti-CD19 autologous chimeric antigen receptor T (CAR-T) cell immunotherapy product Carteyva® (relmacabtagene autoleucel injection)…

thaipr.net

5 ม.ค. 67

Cutting-Edge Gut Microbiome Research: NOSTER’s latest solutions for comprehensive gut bacteria-based metabolite and microbiota analysis

Japan’s Noster Inc., a premier provider of gut microbiome analysis services, is proud to unveil groundbreaking updates in its research on cutting-edge gut bacteria-based metabolite and gut microbiota analysis services. These advancements have far-reaching implications for research on human health and diseases such as diabetes, dietary supplement development, and innovative functional foods. Noster analytics…

thaipr.net

21 ธ.ค. 66

Burjeel Holdings Oncology Conference Marks 10 Years, Focusing on Equitable Solutions for Cancer Care

Experts stress collaboration and innovation are key to progress The 10th anniversary of the Burjeel Holdings Oncology Conference, held in partnership with Foreign Policy, brought together leading global experts to tackle the complex challenges of cancer care, emphasizing the need for multi-stakeholder collaboration. With cancer claiming millions of lives globally, disproportionately impacting low- and middle-income countries, […]

thaipr.net

20 ธ.ค. 66

ACG joins coveted list of WEF’s Global Lighthouse Network

–  Capsule facility in Pithampur, Madhya Pradesh demonstrates excellence in technology enabled operations that transform value chains ACG, the world’s largest integrated supplier and service provider to pharmaceutical industry celebrated the inclusion of its capsule manufacturing facility in Pithampur, India, into the esteemed Global Lighthouse Network (GLN) by the World Economic Forum. WEF’s Global Lighthouse […]

thaipr.net

19 ธ.ค. 66

Biocon Biologics Concludes Integration of Acquired Biosimilars Business in ~120 countries

10+ Emerging Markets, Japan & ANZ Transition in Final Phase Biocon Biologics, a unique, fully integrated, global biosimilars company with a rich portfolio of insulins and monoclonal antibodies, has successfully concluded the integration of the acquired Viatris biosimilars business with the transition of 10+ Emerging Markets and Japan, Australia and New Zealand in the final phase. […]

thaipr.net

19 ธ.ค. 66

BIOCHEETAH ANNOUNCES EXCLUSIVE LICENSING AND COMMERCIALISATION AGREEMENT WITH NIPPON KAYAKU FOR VECanDx™ IN JAPAN

BioCheetah Pte. Ltd. (Head Office: Singapore; CEO: Dr. Lee Kian Chung; hereinafter “BioCheetah”) and Nippon Kayaku Co., Ltd. (Head Office: Tokyo; President: Mr. Atsuhiro Wakumoto; hereinafter “Nippon Kayaku”) announce that the two companies have entered into an exclusive licensing and commercialization agreement to develop and market a novel urinary biomarkers-based bladder cancer diagnostic assay kit, […]

thaipr.net

15 ธ.ค. 66

Menarini Group Presented Initial Safety and Efficacy Data from Phase 1b/2 ELEVATE and ELECTRA Combination Studies of ORSERDU® (Elacestrant) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2023 San Antonio Breast Cancer Symposium

The Menarini Group (“Menarini”), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. (“Stemline”), a wholly-owned subsidiary of the Menarini Group, focused on bringing transformational oncology treatments to cancer patients, presented results from phase 1b/2 ELEVATE and ELECTRA clinical studies evaluating ORSERDU® (elacestrant) in combination with other treatments. Both the…

thaipr.net

13 ธ.ค. 66
1 2 3 4 … 73

Copyright © 2026 Dataxet Limited (บริษัท ดาต้าเซ็ต จำกัด). All Rights Reserved.